Intro: Glucagon-like peptide 1 (GLP-1) agonists are incretin mimetics that bind to GLP-1 receptors to stimulate glucose-dependent insulin release from pancreatic islet cells, inhibit postprandial glucagon level spikes, and suppress appetite by slowing gastric emptying. Currently, the literature has not described the risk of post-endoscopic retrograde cholangiopancreatography (ERCP) complications in type 2 diabetic patients (T2DM) patients. This study aims to assess the risk of post-ERCP complications in T2DM patients on GLP-1 agonists.

Methods: A retrospective cohort study was conducted using TriNetX, a multi-center database of ~110 million patients across 80 healthcare organizations. T2DM Adult patients who underwent an ERCP were identified from 2006-2022 and then split into those with and without 1 1-year history of GLP-1 Agonists. 1:1 propensity score matching was performed, controlling for demographics and comorbidities, to assess 30-day adjusted risk ratios (aRR) for post-ERCP complications which included any episode of gastrointestinal (GI) bleed, post-ercp pancreatitis (PEP), GI perforation, acute kidney injury (AKI), intensive care unit (ICU) admission, sepsis, and all-cause mortality. Patients with prior history of bariatric surgery, DPP-4 inhibitor use and any occurrence of an assessed outcome prior to the study window were excluded from analysis.

Results: Among 32,866 T2DM patients who underwent ERCP, 2.9% had a 1-year history of GLP-1 agonist use. A matched cohort of 965 patients revealed Type 2 Diabetics on GLP-1 agonists had a significantly higher risk of PEP (aRR[95%CI]=1.49[1.2,2.1]) and a significantly lower risk of GI Bleeds (0.57[0.4,0.9]) and mortality (0.59[0.4,0.9]). No differences were seen in GI Perforation (0.99[0.4,2.4]), ICU admission (0.97[0.63,1.5]) or sepsis (0.89[0.6,1.3]).

Conclusion: This study reveals that GLP-1 agonists increase the risk of PEP in T2DM patients. Although it confers some protective effects, potentially holding off GLP-1 therapy prior to procedure may prove beneficial for patients with baseline comorbidities that place them at high risk for pancreatitis. Further studies are warranted to validate these findings.

Sanya Goswami

Appearances